Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5267671
Max Phase: Preclinical
Molecular Formula: C25H30N6O2
Molecular Weight: 446.56
Associated Items:
ID: ALA5267671
Max Phase: Preclinical
Molecular Formula: C25H30N6O2
Molecular Weight: 446.56
Associated Items:
Canonical SMILES: Cc1cc(OCc2nc(N)nc(NCCc3c(C)cccc3C)n2)cc(N2CCCC2=O)c1
Standard InChI: InChI=1S/C25H30N6O2/c1-16-12-19(31-11-5-8-23(31)32)14-20(13-16)33-15-22-28-24(26)30-25(29-22)27-10-9-21-17(2)6-4-7-18(21)3/h4,6-7,12-14H,5,8-11,15H2,1-3H3,(H3,26,27,28,29,30)
Standard InChI Key: BROONYGANMIBKM-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 446.56 | Molecular Weight (Monoisotopic): 446.2430 | AlogP: 3.74 | #Rotatable Bonds: 8 |
Polar Surface Area: 106.26 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 8 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 5.18 | CX LogP: 4.68 | CX LogD: 4.68 |
Aromatic Rings: 3 | Heavy Atoms: 33 | QED Weighted: 0.54 | Np Likeness Score: -1.44 |
1. Lückmann M, Shenol A, Nissen TAD, Petersen JE, Kouvchinov D, Schwartz TW, Frimurer TM.. (2022) Optimization of First-in-Class Dual-Acting FFAR1/FFAR4 Allosteric Modulators with Novel Mode of Action., 13 (12.0): [PMID:36518697] [10.1021/acsmedchemlett.2c00160] |
Source(1):